摘要
目的:观察普萘洛尔口服治疗婴幼儿血管瘤时机选择及安全性的临床研究。方法:选取血管瘤患儿60例,按年龄分组,口服药物1.5mg/kg·d,分2次服药,持续6个月~1年不等。评价其治疗效果,并统计患儿停药后1年生长发育情况与正常同龄幼儿发育状况对比。结果:1岁以内患儿用该方法治疗疗效显著,1岁以上的患儿显效不明显。其中有3例(小于3个月的婴幼儿)因服药后血糖偏低而停止治疗。57例血管瘤患儿身高、体重、头围按"2006年世界卫生组织0~10岁儿童生长标准"表对比均在生长范围内。结论:口服普萘洛尔治疗婴幼儿血管瘤在1岁内治疗安全有效,不良反应少,患儿耐受好,对于小于3个月患儿用药需谨慎观察,通过分析该药对患儿的生长发育不产生任何影响,是一种有效的治疗婴幼儿血管瘤的方法。
Objective To observe the clinical study of timing and safety of propranolol oral treatment for infant hemangioma.Methods Sixty children with hemangioma were use as study group by using propranolol, grouped by age, and at a dose of 1.5 mg/(kg·d), by dividing into 2 times with continuous medication from 6 months to 1 year. To evaluate the therapeutic effect,and to compare the growth and development of the children one year after drug withdrawal with that of the normal children of the same age. Results The therapeutic effect of this method was significant in children under 1 year old, but not in those over1 years old. Three of them(less than 3 months old) stopped treatment because of hypoglycemia. The height, weight and head circumference of 57 children with hemangioma were in the range of growth according to"the World Health Organization(WHO)growth Standard for Children aged 0-10 years 2006". Conclusion Oral propranolol treatment of infant hemangioma within1 year safe and effective, and the adverse effects are minimal. Care should be taken to observe the medication for children younger than 3 months. By analyzing the effect of this drug on the growth and development of children, it is an effective method to treat infant hemangioma.
作者
邹筠
袁华
付荣华
金平亮
ZOU Yun;YUAN Hua;FU Rong-hua;JIN Ping-liang(Department of Plastic Surgery,Jiangxi Provincial Children's Hospital,Nanchang 330006,Jiangxi,China)
出处
《中国美容医学》
CAS
2019年第6期78-80,共3页
Chinese Journal of Aesthetic Medicine
基金
江西省卫生计生委科技计划项目(编号:20143179)
关键词
普萘洛尔
婴幼儿血管瘤
时机选择
安全性
口服
生长发育
propranolol
infantile hemangioma
time choice
safety
oral administration
growth and development
